• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Take­da boots a top prospect out of its late-stage pipeline while an­oth­er is de­layed by war, lock­down

4 years ago
R&D

J&J taps a long­time vet to run its con­sumer health spin­off ahead of next year's sep­a­ra­tion

4 years ago
People
Pharma

As­traZeneca bows first ad cam­paign for lu­pus med Saph­ne­lo, high­lights pa­tients' per­son­al ex­pe­ri­ences

4 years ago
Pharma
Marketing

Cy­ti­va's lat­est project to open in Switzer­land at the end of the month

4 years ago
Pharma
Manufacturing

FDA user fee reau­tho­riza­tions turn in­to rare bi­par­ti­san love­fest at House hear­ing

4 years ago
FDA+

Wis­con­sin giv­ing Ar­row­head Phar­ma­ceu­ti­cals some ched­dar as their new man­u­fac­tur­ing site re­ceives sev­er­al mil­lion in ...

4 years ago
Pharma
Manufacturing

Mod­er­na's new CFO out af­ter for­mer em­ploy­er un­veils in­ter­nal au­dit­ing in­ves­ti­ga­tion

4 years ago
People
Pharma

For­mer Im­munomedics CFO Us­ama Ma­lik in­dict­ed for al­leged­ly giv­ing ex-girl­friend in­sid­er in­fo

4 years ago
People

The col­lapse of SKY­SCRAPER-01 is cast­ing a pall over all the TIG­ITs. Are we in for an­oth­er I/O fi­as­co?

4 years ago
Bioregnum
R&D

Covid-19 roundup: Can­cer biotech to sub­mit EUA for Covid drug; FDA OKs Eli Lil­ly JAK in­hibitor

4 years ago
Coronavirus

Iterum says FDA is in 'gen­er­al align­men­t' on pro­posed new PhI­II for re­ject­ed uU­TI drug

4 years ago
R&D

FDA hits Am­i­cus with de­lay on 'break­through' Pompe drug

4 years ago
FDA+

As­traZeneca and Sanofi sharp­en RSV pitch with new analy­ses, but how much weight will FDA give them?

4 years ago
R&D

With 30-year in­dus­try chops, Pamela Con­ley launch­es a pro­tein ther­a­peu­tics biotech for au­toim­mune dis­eases

4 years ago
Financing
Startups

In­ovio's long­time CEO is out as Covid vac­cine lag­gard throws in the tow­el on PhI­II, piv­ots to boost­er

4 years ago
People

Roche goes 0-2 in the high-stakes race to get a TIG­IT through PhI­II and on­to the mar­ket

4 years ago
R&D

Scoop: Green Val­ley's sea­weed-de­rived Alzheimer's drug, ap­proved in Chi­na, is halt­ed in PhI­II study

4 years ago
R&D
China

Bausch Health stock plum­mets even as com­pa­ny looks to start 'new chap­ter'

4 years ago
Pharma

Just months af­ter its first FDA ap­proval, Idor­sia dumps binge-eat­ing drug can­di­date af­ter PhII fail

4 years ago
R&D

Sun Phar­ma site hit with sec­ond Form 483 in 3 years

4 years ago
Pharma
Manufacturing

Emer­gent tossed near­ly 400M Covid-19 vac­cine dos­es in Bal­ti­more de­ba­cle, House re­port says

4 years ago
Pharma
Coronavirus

CSL, plas­ma com­pa­nies win re­ver­sal on suit over Bor­der Pa­trol block­ade of visas for paid col­lec­tions

4 years ago
Pharma
Law

UCB de­tails pos­i­tive piv­otal da­ta for myas­the­nia gravis, days af­ter As­traZeneca scores OK for Soliris suc­ces­sor

4 years ago
Pharma

ICER: Mer­ck­'s Covid-19 pill does­n't show 'net health ben­e­fit' but price is rea­son­able

4 years ago
Pharma
Coronavirus
First page Previous page 533534535536537538539 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times